Seismic Shift: Innovations in MRD Testing and Pathology

Join OncoDaily, in partnership with Natera for an insightful webinar on the evolving role of Molecular Residual Disease (MRD) testing.

Molecular Residual Disease (MRD) testing is rapidly transforming cancer care, shifting patient management from broad population-based risk stratification toward highly targeted, precision monitoring. Presented in collaboration with Natera, a pioneer in cell-free DNA and personalized MRD technology, this session features Dr. Joe Lennerz detailing the key technological advances and clinical strategies driving this paradigm shift. Attendees will gain a clear understanding of how emerging liquid biopsy methodologies, high-sensitivity digital platforms, and integrated pathology workflows are overcoming traditional diagnostic limitations. The session will also highlight practical approaches to optimizing tissue stewardship, streamlining specimen logistics, and establishing standardized reporting to ensure consistent, actionable insights for patient care.

Date: November 6, 08:00 AM PT
Live Platform: X (OncoDaily)
Presenster: Joe Lennerz (Medical Director for Pathology Innovations at Natera)
Host: Sona Karamyan (OncoDaily)

Who Should Attend

This session is designed for oncologists, surgical and molecular pathologists, clinical laboratory directors, diagnostic researchers, and healthcare professionals seeking to integrate modern MRD testing strategies into clinical practice.